Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials

Journal of Clinical Oncology

Volumn 29, Issue 2, 2011, Pages 174-185

  Seruga, Bostjan ^a   Sterling, Lynn ^a   Wang, Lisa ^a   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; DASATINIB; ERLOTINIB; IBRITUMOMAB TIUXETAN; IMATINIB; LAPATINIB; PANITUMUMAB; RITUXIMAB; SUNITINIB; TRASTUZUMAB;

ACUTE DIFFUSE INFILTRATIVE LUNG DISEASE; ADRENAL INSUFFICIENCY; ADVERSE DRUG REACTION; ANGINA PECTORIS; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BULLOUS SKIN DISEASE; CARDIOMYOPATHY; CARDIOPULMONARY ARREST; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CORNEA PERFORATION; CYTOPENIA; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG FATALITY; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTROLYTE DISTURBANCE; FISTULA; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPOTENSION; HYPOTHYROIDISM; INFECTION; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; KIDNEY FAILURE; LEUKEMIA; LIVER DISEASE; LIVER TOXICITY; LUNG DISEASE; LUNG FIBROSIS; LUNG TOXICITY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SKIN MANIFESTATION; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TORSADE DES POINTES; TUMOR LYSIS SYNDROME; VIRUS REACTIVATION; WOUND HEALING IMPAIRMENT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG LABELING; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79951981575     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.9624     Document Type: Article

References (56)

1. Sobrero A, Bruzzi P: Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 27:5868-5873, 2009
2. Ioannidis JP, Evans SJ, Gøtzsche PC, et al: Better reporting of harms in randomized trials: An extension of the CONSORT statement. Ann Intern Med 141:781-788, 2004 (Pubitemid 39524916)
3. Berlin JA, Glasser SC, Ellenberg SS: Adverse event detection in drug development: Recommendations and obligations beyond phase 3. Am J Public Health 98:1366-1371, 2008
4. Ioannidis JP: Adverse events in randomized trials: Neglected, restricted, distorted, and silenced. Arch Intern Med 169:1737-1739, 2009
5. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. http://www.fda.gov/Safety/MedWatch/default.htm
6. Härmark L, van Grootheest AC: Pharmacovigilance: Methods, recent developments and future perspectives. Eur J Clin Pharmacol 64:743-752, 2008
7. US Food and Drug Administration: FDA approved drug products. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
8. Zielinski SL: FDA attempting to overcome major roadblocks in monitoring drug safety. J Natl Cancer Inst 97:872-873, 2005
9. US Food and Drug Administration: Guidance for Industry: Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products - Content and format. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm075096.pdf
10. National Cancer Institute: Common Toxicity Criteria (CTC) version 2.0. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcv20-4-30-992.pdf
11. National Cancer Institute: Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
12. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
13. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
14. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
15. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007 (Pubitemid 46733080)
16. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370:2103-2111, 2007 (Pubitemid 350296300)
17. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
18. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005 (Pubitemid 41007864)
19. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
20. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004 (Pubitemid 38944402)
21. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
22. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007 (Pubitemid 350106711)
23. Shah NP, Kantarjian HM, Kim DW, et al: Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronicphase chronic myeloid leukemia. J Clin Oncol 26: 3204-3212, 2008
24. Kantarjian H, Cortes J, Kim DW, et al: Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113: 6322-6329, 2009
25. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
26. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892-5899, 2005
27. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non - small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552, 2007 (Pubitemid 46733081)
28. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
29. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463, 2002 (Pubitemid 34525730)
30. Morschhauser F, Radford J, Van Hoof A, et al: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008
31. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003 (Pubitemid 36302244)
32. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004 (Pubitemid 39296599)
33. Blanke CD, Rankin C, Demetri GD, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632, 2008 (Pubitemid 351264358)
34. Dematteo RP, Ballman KV, Antonescu CR, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 373:1097-1104, 2009
35. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
36. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007 (Pubitemid 46797944)
37. Hecht JR, Mitchell E, Chidiac T, et al: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672-680, 2009
38. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
39. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
40. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
41. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006 (Pubitemid 46638950)
42. Hochster H, Weller E, Gascoyne RD, et al: Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 Study. J Clin Oncol 27:1607-1614, 2009
43. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006 (Pubitemid 44528723)
44. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
45. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
46. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
47. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005 (Pubitemid 41464706)
48. Lasser KE, Allen PD, Woolhandler SJ, et al: Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220, 2002 (Pubitemid 34441937)
49. Glasser SP, Salas M, Delzell E: Importance and challenges of studying marketed drugs: What is a phase IV study? Common clinical research designs, registries, and self-reporting systems. J Clin Pharmacol 47:1074-1086, 2007
50. Wood AJ: Thrombotic thrombocytopenic purpura and clopidogrel: A need for new approaches to drug safety. N Engl J Med 342:1824-1826, 2000
51. Tsang R, Colley L, Lynd LD: Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials. J Clin Epidemiol 62:609-616, 2009
52. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
53. US Food and Drug Administration: Label and Approval History of Arimidex. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020541s024s025lbl.pdf
54. Bassler D, Briel M, Montori VM, et al: Stopping randomized trials early for benefit and estimation of treatment effects: Systematic review and metaregression analysis. JAMA 303:1180-1187, 2010
55. Van Spall HG, Toren A, Kiss A, et al: Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review. JAMA 297:1233-1240, 2007
56. Duff JM, Leather H, Walden EO, et al: Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. J Natl Cancer Inst 102:702-705, 2010